Benzinga's M&A Chatter for Thursday February 25, 2016

The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday February 25, 2016: Sanofi in Talks to Acquire PTC Therapeutics The Rumor:
Sanofi SA SNY is in talks to acquire PTC Therapeutics, Inc. PTCT, according to a source familiar with the matter as reported by Benzinga on Thursday. The two companies began talks earlier this week after PTC said it received a Refuse to File notice from the FDA regarding Translarna, the source said. Société Générale is said to be assisting PTC Therapeutics in the negotiations. A Sanofi spokesperson declined comment on the report. PTC Therapeutics did not respond to request for comment. PTC Therapeutics closed at $51.36 on Thursday, up $0.18. Energy Transfer Said to be Considering Pulling Out of Williams Deal The Rumor:
Energy Transfer Equity ETE has considered offering a one-time payment more than $2 billion to Williams Cos WMB to back out of its acquisition deal, according sources as reported by the NY Times Dealbook on Thursday. Since ETE agreed to buy Williams for $32.9 billion, in September 2015, shares of the two companies have lost a combines $37 billion in market value. The dramatic decline was due to the collapse in the price of oil and also on investor concerns over the deal. Energy Transfer Equity shares fell 5% on Thursday, to close at $6.80. Williams share fell 3.61% to close at $16.03. Rouse Properties to be Acquired by an Affiliate of Brookfield Asset Management for $18.25/Share in Cash The Deal:
Rouse Properties, Inc. RSE announced Thursday it has agreed to be acquired by an affiliate of Brookfield Asset Management Inc. BAM for $18.25 per share in cash. The transaction is valued at approximately $2.8 billion. Brookfield's had originally offered $17.00 per share for Rouse. The transaction is expected to close during Q3 of 2016. Rouse closed at $18.40 on Thursday, up 3.66%. Mckesson to Acquire Vantage Oncology And Biologics in Two Transactions Totaling $1.2B The Deal:
McKesson Corporation MCK announced Thursday, that it has signed definitive agreements to acquire Vantage Oncology, LLC and Biologics, Inc. The two transactions, valued at $1.2 billion, are expected to close in Q1 of Fiscal 2017. Mckesson closed at $155.37 on Thursday, up $0.70.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsRumorsM&AMoversHealth CareHealth Care Distributors
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!